FDA approves belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component

Coverage, in order

1. 5d ago
   first FDA Drug Safety / Drugs feed indie

   FDA approves belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component

   On September 24, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with lenvatinib (Lenvima, Eisai Inc.) for adults with advanced renal cell carcinoma with a clear cell component (ccRCC).

2. 5d ago
   FDA Drug Safety / Drugs feed indie

   FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma

   On June 12, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the adjuvant treatment of adults with renal cell

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.